Urban Health Research at the New York Academy of Medicine

Institute for Urban Health pic

Institute for Urban Health
Image: nyam.org

A health care executive based in New York City, Dr. Mitchell Blutt serves as the chief executive officer of Consonance Capital. Dr. Mitchell Blutt is also a member of the New York Academy of Medicine, a nonprofit organization dedicated to improving the overall health of people living in urban settings.

The New York Academy of Medicine hosts the Institute for Urban Health, a policy organization designed to create innovative solutions to health issues in cities. The Institute for Urban Health takes a collaborative, interdisciplinary approach to improving urban health. In particular, the Institute focuses on matters such as increasing preventive care and healthy aging and eliminating health disparities.

To accomplish its mission, the Institute for Urban Health conducts a variety of studies using quantitative and qualitative research. The organization partners chiefly with health care systems and health departments across New York City, as well as local universities and community organizations. The Institute for Urban Health performs its research through units such as the Center for Health Innovation, which focuses on the most important determinants of health on a broad scale.


Joe Biden Will Become a Professor at the University of Pennsylvania

Joe Biden Will Become a Professor at the University of Pennsylvania

A clinical assistant professor of medicine at Weill Cornell Medical College, Mitchell Blutt, MD, focuses on preparing the next generation of physicians. In addition, he is the founder and CEO of Consonance Capital, where he aims to advance the field of health care investment. Possessing a BA, MD, and MBA from the University of Pennsylvania, Mitchell Blutt, MD, remains heavily involved with his alma mater as a former trustee of the university and its School of Medicine, as well as a member of the board of overseers for the School of Arts and Sciences. Recently, the University of Pennsylvania announced that it will welcome former Vice President Joe Biden as its Benjamin Franklin Presidential Practice Professor and that he will direct the university’s Penn Biden Center for Diplomacy and Global Engagement. While the center will be based in Washington, D. C., Biden will maintain an office at Penn’s Philadelphia campus. Focused on both teaching and research, the new center will guide students in the exploration of foreign policy, diplomacy, and national security while at the same time partnering with global leaders and academic centers to solve international challenges. As a professor at Penn, he will hold joint appointments with the School of Arts and Sciences and the Annenberg School for Communication.The new role will allow Biden to maintain his commitment to public service, which has included defending the stability of the post-WWII international order while solving domestic issues at home. He served as a senator from Delaware for 36 years, which included 12 years as a chairman or ranking member of the Senate Foreign Relations Committee and 17 years as a chairman or ranking member of the Senate Judiciary Committee. As the 47th vice president of the United States, Mr. Biden provided vital guidance to President Barack Obama about international affairs. In addition, he represented the country around the world and oversaw vital domestic endeavors such as the American Recovery and Reinvestment Act’s economic stimulus package.

Michael J. Fox Foundation Launches Partnership to Study Nilotinib

Michael J. Fox Foundation pic

Michael J. Fox Foundation
Image: michaeljfox.org

For over a decade, Dr. Mitchell Blutt has served as chief executive officer of Consonance Capital, a health care investment firm based in New York City. Alongside his professional activities, Dr. Mitchell Blutt has dedicated his time and resources to a number of organizations over the years, including the Michael J. Fox Foundation (MJFF).

In a recently released statement, MJFF announced that it is collaborating with the Van Andel Research Institute and the Cure Parkinson’s Trust to assess the effectiveness of nilotinib, a cancer drug that inhibits a protein also associated with Parkinson’s disease. Previous research on nilotinib has shown that the drug is well tolerated and has the potential to improve the motor skills and cognitive function of individuals with Parkinson’s.

As part of the collaboration, MJFF and its partner organizations hope to launch a double-blind, placebo-controlled clinical trial of the drug in 2017. MJFF will host a webinar on nilotinib later this summer and will keep the Parkinson’s community updated on developments through its website and social media channels. For more information, visit www.michaeljfox.org.